Predictors of Acute Esophagitis in Lung Cancer Patients Treated With Concurrent Three-Dimensional Conformal Radiotherapy and Chemotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 3, 2009, Pages 810-817

  Rodríguez, Núria ^a,b   Algara, Manuel ^a,c   Foro, Palmira ^a   Lacruz, Marti ^a,c   Reig, Anna ^a   Membrive, Ismael ^a   Lozano, Joan ^a   López, José Luis ^a   Quera, Jaime ^a,c   Fernández Velilla, Enric ^a   Sanz, Xavier ^a  

^a HOSPITAL DE L ESPERANÇA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

3D conformal radiotherapy; Concurrent chemotherapy; Dosimetric parameter; Esophagitis; Lung cancer

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DOSIMETERS; DOSIMETRY; PATIENT MONITORING; RADIOTHERAPY;

3D-CONFORMAL RADIOTHERAPY; CONCURRENT CHEMOTHERAPY; DOSIMETRIC PARAMETER; ESOPHAGITIS; LUNG CANCER;

THREE DIMENSIONAL;

ANALGESIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE DURATION; DOSIMETRY; ESOPHAGITIS; ESOPHAGUS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION FIELD; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TUMOR VOLUME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGITIS; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; ROC CURVE; SMALL CELL LUNG CARCINOMA; TUMOR BURDEN; VINBLASTINE;

EID: 59749088859     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.04.064     Document Type: Article

References (36)

1. Delaney G., Barton M., Jacob S., et al. A model for decision making for the use of radiotherapy in lung cancer. Lancet Oncol 4 (2003) 120-128
2. Schaake-Koning C., Van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326 (1992) 524-530
3. Emami B., and Graham M.V. Lung. In: Perez C.A., and Brady L.W. (Eds). Principles and practice of radiation oncology. 3rd ed. (1998), Lippincott-Raven, Philadelphia 1181-1220
4. Byhardt R.W., Scott C., Sause W.T., et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42 (1998) 469-478
5. Algara M., Rodríguez N., Viñals P.M., et al. Prevention of radiochemotherapy induced esophagitis with glutamine. Pilot study. Int J Radiat Oncol Biol Phys 69 (2007) 342-349
6. Bowden P., Fischer R., Mac M.M., et al. Measurement of lung tumor volumes using three dimensional computer planning software. Int J Radiat Oncol Biol Phys 53 (2002) 566-573
7. Rodríguez N., Foro P., Sanz X., and Algara M. Target contouring protocol for 3D conformal radiotherapy in lung cancer. Int J Radiat Oncol Biol Phys 65 (2006) 1275-1276
8. Faria S.L., Menard S., Devic S., et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small cell ling cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys 70 (2008) 1035-1038
9. Rodríguez G., Lock M., D'Souza D., et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 71 (2004) 127-138
10. Metha V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
11. Cox J.D., Stetz J., Pajak T.F., et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
12. Werner-Wasik M., Pequignot E., Leeper D., Hauck W., et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiatiated esophagus: A multivariate analysis of patients with lung cancer treated with non-operative therapy. Int J Radiat Oncol Biol Phys 48 (2000) 689-696
13. Greiner M., Pfeiffer D., Smith R.D., et al. Principles and practical application of the receiver operating characteristic analysis for diagnostic test. Prev Vet Med 45 (2000) 23-41
14. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 (1991) 109-122
15. Pallares C., Capdevila J., Paredes A., et al. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial. Lung Cancer 58 (2007) 238-245
16. Blanco R, Solé J, Montesinos J, et al. Induction chemotherapy with cisplatin and gemcitabina followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study. Lung Cancer (in press).
17. Komaki R., Seiferheld W., Ettinger D., et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small cell lung cancer. Long-term follow up of RTOG 92-04. Int J Radiat Oncol Biol Phys 53 (2002) 548-557
18. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323 (1990) 940-945
19. Sause W., Kolesar P., Taylor IV S., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 (2000) 358-364
20. Bradley J., Deasy J.O., Bentzen S., et al. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 58 (2004) 1106-1113
21. Singh A.K., Lockett M.A., and Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients in patients with non-small cell lung cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 55 (2003) 337-341
22. Patel A., Edelman M., Kwok Y., et al. Predictors of acute esophagitis in patients with non small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 60 (2004) 1106-1112
23. Ahn S., Kahn D., Zhou S., et al. Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 61 (2005) 335-347
24. Vokes E.E., Herndon J.E., Crawford J., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 20 (2002) 4191-4198
25. Dorr W., and Hendry J.H. Consequential late effects in normal tissues. Radiother Oncol 61 (2001) 223-231
26. Umsawasdi T., Valdivieso M., Barkley H.T., et al. Esophageal complications from combined chemotherapy (cyclophosphamide + adriamicyn + cisplatin + XRT) in the treatment of nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 11 (1985) 511-519
27. Ball D., Bishop J., Smith J., et al. A phase III study of accelerated radiotherapy ith and without carboplatin in non-small cell lung cancer: An interim toxicity analysis of the first 100 patients. Int J Radiat Oncol Biol Phys 31 (1995) 267-272
28. Choy H., LaPorte K., Knill-Selby E., et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9 (1999) 90-96
29. Langer C.J. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 9 (1999) 108-116
30. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non small cell lung cancer. Am J Clin Oncol 30 (2007) 239-244
31. Hirota S., Tsujino K., Endo M., et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 51 (2001) 291-295
32. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45 (1999) 97-103
33. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
34. Wei X., Liu H., Tucker S., et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 100-107
35. Kim T.H., Cho K.H., Pyo H.R., et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 995-1002
36. Takeda K., Remoto K., Saito H., et al. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 626-629